Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
Randomized Double Blind Phase III Trial Comparative Clinical Safety, Efficacy and Immunogenicity of Adalimumab (Manufactured by Mabscale, LLC) to Humira®.
Sponsor: Mabscale, LLC
This PHASE3 trial investigates Plaque Psoriasis and is currently ongoing. Mabscale, LLC leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Oct 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mabscale, LLC
For direct contact, visit the study record on ClinicalTrials.gov .